BALTIMORE, May 22, 2018 – Elixirgen Scientific’s new kit, Quick-miniBrain™ uses ES/iPSC differentiation to form miniaturized, 3D human brain tissues for drug discovery and toxicity screening. 3D organoid development is an active area of research in life sciences; its potential to reduce drug development costs by improving predictability of drug efficacy and toxicity screening and its potential use in regenerative medicine, such as in transplantation and personalized medicine, has made it a hot field for academia, private institutions, and government institutions alike.
Currently, unresolved issues in production speed, reproducibility, and economy hinder the growth and advancement of 3D organoid development. The Quick-miniBrain™ kit will be the solution for such issues. The Quick-miniBrain™ kit provides 3D mini-brain organoids in 14 days from ESCs/iPSCs at under $900 for the kit itself. Researchers can use their own ESCs/iPSCs to form 3D mini-brain organoids for research into the disease of their choice. The kit works equally well with all ES/iPSC lines with quality pluripotency. For example, ESCs and iPSCs modified by CRISPR/Cas9 can be used to generate 3D mini-brains.
By combining Elixirgen Scientific’s other products/services, researchers can get disease patient-derived mini-brain models produced with iPSCs from the California Institute for Regenerative Medicine’s (CIRM) hPSC repository and or already-differentiating mini-brains through Elixirgen Scientific’s cell differentiation services.